References
1. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma.Pulmonary Pharmacology & Therapeutics. 2001;14(1):3-19.
2. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. Med Res Rev. 2007;27(4):469-527.
3. Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A. Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med. 2000;161(2 Pt 2):S112-116.
4. Back M. Leukotriene signaling in atherosclerosis and ischemia.Cardiovasc Drugs Ther. 2009;23(1):41-48.
5. Poeckel D, Funk CD. The 5-Lipoxygenase/Leukotriene Pathway in Preclinical Models of Cardiovascular Disease. Cardiovasc Res.2010.
6. Capra V, Back M, Barbieri SS, Camera M, Tremoli E, Rovati GE. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev. 2013;33(2):364-438.
7. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy.Circulation. 1992;86(1):56-63.
8. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.Circulation. 1992;85(1):230-236.
9. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis.1993;4(10):899-904.
10. De Caterina R, Giannessi D, Lazzerini G, et al. Sulfido-peptide leukotrienes in coronary heart disease - relationship with disease instability and myocardial ischaemia. Eur J Clin Invest.2010;40(3):258-272.
11. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries.Circulation. 1998;97(24):2406-2413.
12. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol.2003;23(8):e32-36.
13. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100(3):1238-1243.
14. Di Gennaro A, Wagsater D, Mayranpaa MI, et al. Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc Natl Acad Sci U S A. 2010;107(49):21093-21097.
15. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36(3):233-239.
16. Iovannisci DM, Lammer EJ, Steiner L, et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study. Arterioscler Thromb Vasc Biol. 2007;27(2):394-399.
17. Bevan S, Lorenz MW, Sitzer M, Markus HS. Genetic variation in the leukotriene pathway and carotid intima-media thickness: a 2-stage replication study. Stroke. 2009;40(3):696-701.
18. Freiberg JJ, Tybjaerg-Hansen A, Nordestgaard BG. Novel mutations in leukotriene C(4) synthase and risk of cardiovascular disease based on genotypes from 50,000 individuals. J Thromb Haemost.2010;8(8):1694-1701.
19. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities.Curr Med Chem. 2006;13(26):3213-3226.
20. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
21. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis.Nat Rev Cardiol. 2015;12(4):199-211.
22. Sala A, Rossoni G, Berti F, et al. Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness.Circulation. 2000;101(12):1436-1440.
23. Bäck M. Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal. 2007;7:1422-1439.
24. Back M, Powell WS, Dahlen SE, et al. International Union of Basic and Clinical Pharmacology. Update on Leukotriene, Lipoxin and Oxoeicosanoid Receptors: IUPHAR Review 7. Br J Pharmacol.2014;171(15):3551-3574.
25. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4(8):664-672.
26. Back M, Dahlen SE, Drazen JM, et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev.2011;63(3):539-584.
27. Di X, Tang X, Di X. Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosis. Biochem Biophys Res Commun. 2017;486(1):58-62.
28. Di Gennaro A, Araujo AC, Busch A, et al. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.Proc Natl Acad Sci U S A. 2018;115(8):1907-1912.
29. Hoxha M, Rovati GE, Cavanillas AB. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol. 2017;73:799-809.
30. Allayee H, Hartiala J, Lee W, et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132(3):868-874.
31. Ingelsson E, Yin L, Back M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol.2012;129(3):702-707.
32. Tajeu GS, Booth JN, 3rd, Colantonio LD, et al. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation. 2017;136(9):798-812.
33. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150-161.
34. Rovati GE, Sala A, Capra V, Dahlen SE, Folco G. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends Pharmacol Sci. 2010;31(3):102-107.
35. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. Jama.2005;293(18):2245-2256.
36. Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol. 2012;176(11):1014-1024.
37. Tattersall MC, Guo M, Korcarz CE, et al. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol.2015;35(6):1520-1525.
38. Dhingra R, Vasan RS. Age as a risk factor. Med Clin North Am.2012;96(1):87-91.
39. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568-579.